Principal Financial Group Inc. Has $21.46 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Principal Financial Group Inc. increased its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 791,134 shares of the company's stock after purchasing an additional 245,775 shares during the quarter. Principal Financial Group Inc. owned approximately 1.38% of Structure Therapeutics worth $21,456,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after purchasing an additional 312 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares in the last quarter. Money Concepts Capital Corp raised its holdings in shares of Structure Therapeutics by 4.2% in the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after buying an additional 848 shares in the last quarter. GAMMA Investing LLC grew its position in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Structure Therapeutics by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,634 shares of the company's stock worth $343,000 after buying an additional 1,174 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research analysts have commented on the stock. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. JMP Securities reissued a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Stock Up 14.8 %

Structure Therapeutics stock traded up $2.94 during mid-day trading on Thursday, hitting $22.82. The company's stock had a trading volume of 1,591,478 shares, compared to its average volume of 797,217. The stock has a market capitalization of $1.31 billion, a P/E ratio of -30.84 and a beta of -2.75. Structure Therapeutics Inc. has a twelve month low of $19.61 and a twelve month high of $62.74. The stock's fifty day moving average price is $26.80 and its two-hundred day moving average price is $33.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.